GlassScriptPhysician profile
William Norman Ginn
NPI 1003907585
$9,742.58
in general payments reported to CMS, 2019-2025
28 companies · $1,892 in 2025
The $1,892 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,131 · 2020: $1,097 · 2021: $1,169 · 2022: $1,423 · 2023: $1,230 · 2024: $1,801 · 2025: $1,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,747 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,747.44 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,142.23 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,024.01 | 2021-2025 | |
| Pfizer INC. | $772.80 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $739.50 | 2019-2025 | Jardiance, Tradjenta, Jascayd |
| Novo Nordisk INC | $614.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $541.96 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $395.59 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $325.00 | 2020-2025 | Prolia, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $307.02 | 2019-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Phathom Pharmaceuticals, INC. | $284.90 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $268.20 | 2019-2022 | |
| Abbott Laboratories | $233.65 | 2021-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $203.12 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $179.44 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $142.72 | 2024-2025 | Zoryve |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $115.12 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $80.58 | 2022-2024 | Eliquis |
| Novartis Pharmaceuticals Corporation | $75.96 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $54.35 | 2022 | |
| Astellas Pharma US INC | $50.29 | 2024 | Veozah |
| Allergan, INC. | $42.94 | 2019 | |
| Axsome Therapeutics, INC. | $34.15 | 2025 | Auvelity |
| Nestle Healthcare Nutrition INC. | $28.72 | 2021-2022 | |
| Genentech USA, INC. | $23.09 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.49 | 2025 | |
| Corium, LLC | $16.96 | 2023 | Azstarys |
| Bausch Health US, LLC | $13.77 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ginn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.